| Budget Amount *help |
¥17,160,000 (Direct Cost: ¥13,200,000、Indirect Cost: ¥3,960,000)
Fiscal Year 2021: ¥3,250,000 (Direct Cost: ¥2,500,000、Indirect Cost: ¥750,000)
Fiscal Year 2020: ¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2019: ¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2018: ¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
|
|---|
| Outline of Final Research Achievements |
Our hypothesis is that fibrosis within tumour tissue is an important determinant of clinical drug efficacy. We worked on the verification of this hypothesis through three-dimensional culture of its constituent cells, pancreatic stellate cells (PSCs). Specifically, the thickness of fibrotic tissue was measured in human cases and three-dimensional cultured tissue with equivalent thickness was created. The ECM proteins involved in fibrosis were visualised and analysed in the fibrotic tissue model, and differences between pancreatic cancer-derived PSCs and normal fibroblasts were revealed. We developed a three-dimensional co-culture model between PSCs and pancreatic cancer cells, and succeeded in creating three-dimensional co-cultured tissue that reproduced the range of tumour tissue occupancy rates observed clinically. Consequently, we were able to reproduce and analyse mechanism of the acquisition of PSC trait abnormalities by co-culturing with pancreatic cancer cells.
|
